Advisory Committee on Immunization Practices (ACIP)

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES
Centers for Disease Control and Prevention
1600 Clifton Road, N.E.
Tom Harkin Global Communications Center, Kent “Oz” Nelson Auditorium
Atlanta, Georgia 30329
June 20-21, 2018
ACIP Meeting Information

The ACIP holds three meetings each year at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia to review scientific data and vote on vaccine recommendations. Meetings are open to the public and available online via live webcast. During committee meetings, members present findings and discuss vaccine research and scientific data related to vaccine effectiveness and safety, clinical trial results, and manufacturer’s labeling or package insert information. Outbreaks of vaccine-preventable disease or changes in vaccine supply also are reviewed during these meetings. Vaccine recommendations include the age(s) when the vaccine should be given, number of doses needed, dosing interval, and precautions and contraindications to administration of vaccines.

Meeting Agendas

- February 22-23, 2017 [2 pages]
- October 19-20, 2016 [2 pages]
- June 22-23, 2016 [2 pages]

Meeting Minutes
ACIP

The Advisory Committee on Immunization Practices (ACIP) is a group of medical and public health experts that develop recommendations on use of vaccines in the civilian population of the United States...

Register for upcoming October ACIP meeting
October 24-25, 2018

Deadline for registration:
Non-US Citizens: September 26, 2018
US Citizens: October 10, 2018

Registration is NOT required to watch the live meeting webcast or to listen via telephone.

Live Webcast Instructions

Public Comment Instructions  

On November 9, 2017, FDA approved a new hepatitis B vaccine, HEPLISAV-B®, for use in adults 18 years of age and older. HEPLISAV-B® is the first licensed vaccine using a CpG adjuvant* and is administered as two doses given one month apart. Further details on this vaccine’s approval can be found at Vaccines Licensed for Use in the United States®.

* Cytosine phosphoehexylic (CpG) 1018 adjuvant.

February 2018 Meeting Recommendations

ACIP approved the following recommendations by majority vote at its February 2018 meeting:

- For the 2018-2019 influenza season, immunization providers are recommended to administer any licensed, age-appropriate influenza vaccine (IV, RIV, or LAIV). LAIV is an option for influenza vaccination for persons

Get Email Updates
Ex-Officio and Liaison Representatives

• NIH: Dr. John Beigel, Associate Director for Clinical Research, Division of Microbiology and Infectious Diseases, NIAID

• IHS: Dr. Tom Weiser, Medical Epidemiologist, Northwest Tribal Epidemiology Center
Member Substitutions for this Meeting

Liaison Representatives
  – James Campbell, MD, FAAP, AAP COID

Ex-officio Members
  – Dr. Mary Rubin, HRSA
Guest Attendees at this Meeting

• Dr. Joachim Hombach, Executive Secretary, WHO Strategic Advisory Group of Experts on Immunization (SAGE)

• Iwona Paradowska-Stankiewicz, Deputy Head of Epidemiology Department, Head of the Vaccine Preventable Disease Unit, Poland National Institute of Public Health
Dr. Ed Belongia:

- Flu Work Group
- Chair, Zoster Work Group
Dr. Laura Riley

• HPV Work Group
• Cholera Work Group
• RSV Work Group
• Chair, Adult Schedule Work Group
Ms. Cynthia Pellegrini

- Mumps Work Group
- Flavivirus Work Group
- Child/adolescent Schedule Work Group
- General Recommendations
- HPV Work Group
Process for Public Comment

• Public comment period is scheduled immediately preceding each ACIP vote and at end of meeting day
  – Registration for public comments is solicited in advance of the meeting
  – Comments not presented at meeting may be submitted for inclusion in the minutes

• Individuals should limit to a single public comment, 3 minutes in total in length
  – If you wish to make a public comment, please complete a form at the back of the room
Disclosure of Conflicts of Interest

• Members of the ACIP agree to forgo participation in certain activities related to vaccines during their tenure on the committee. CDC has issued limited conflict of interest waivers as follows:
  
  – Members who conduct vaccine clinical trials or serve on data safety monitoring boards are prohibited from participating in committee votes related to those vaccines.
  
  – Regarding other vaccines of the concerned company, a member may participate in discussions, with the provision that he/she abstains on all votes related to the vaccines of that company.

• At the beginning of each meeting, ACIP members state any conflicts of interest.
ACIP Membership

Advisory Committee on Immunization Practices (ACIP)

Application for Membership on ACIP

ACIP: Membership Application Procedure

The procedure for application to serve as a voting member of the Advisory Committee on Immunization Practices (ACIP) is addressed in the web letter below.

The deadline for consideration of ACIP applications (Term of July 1, 2019-June 30, 2023) is August 1, 2018

- Letter for solicitation of ACIP membership candidates [2 pages] Updated Jan 2018
- Detailed information regarding ACIP membership [9 pages] Updated Jan 2016

The above letter has the following attachment:

- Professional area breakdown [1 page] Updated Oct 2016
Please Turn off Your Cell Phones....